State AGs urge HHS to sidestep Gilead patents to boost remdesivir access
A bipartisan group of state attorneys general is urging the federal government to sidestep Gilead’s remdesivir patents to increase access to the drug.
Related Articles
Cattle testing for H5N1 bird flu will be more limited than USDA initially announced
The USDA order mandating H5N1 bird flu testing in dairy cows is less stringent than initially described by the agency.
Hospitals largely keep quiet on maternal care since Dobbs, STAT survey finds
Of 100 hospitals across 50 states surveyed by STAT about changes in maternal care after overturning of Roe v. Wade, only six agreed to speak.
STAT in DC: Policy in Health Care
Join STAT’s leading DC bureau as they take the stage with policymakers, patient advocates, and industry experts to discuss the biggest issues in health policy…
Momentum builds for House bill cracking down on Chinese biotechs
House lawmakers are aiming to pass the BIOSECURE ACT in time for it to be included in a year-end must-pass legislative package.
Another hospital sues MultiPlan, alleging scheme to ‘suppress’ payments
MultiPlan faces a class action lawsuit alleging the company and insurers “conspired to fix, suppress, and stabilize” medical payments.
To rebuild trust in public health: Better communication, fewer mandates, and small wins
Rebuilding trust in the CDC won’t be quick or easy — especially in a divisive political season — but that doesn’t make it any less…
Mental health crisis centers and EmPATH units: offering care that busy ERs can’t
As national awareness of mental illness rises and innovative care models emerge, many advocates now see a rare opportunity to remake mental health crisis care…
After AI protein folding, David Baker’s lab identifies millions of smaller drug candidates
A new Science paper from the Baker lab details a novel method for quickly compiling a large library of macrocycle drug candidates.
Pharmalittle: We’re reading about Cigna biosimilar plans, a Vertex deal in South Africa, and more
Cigna plans to make copies of AbbVie’s Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
Sharon Begley Science Reporting Fellowship
Boston, Mass. STAT, the leading health and science news publication, and the Knight Science Journalism Program at the Massachusetts Institute of